key: cord-1032898-vnshs7xx
authors: Yang, Stephen Su; Lipes, Jed
title: Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series
date: 2020-05-11
journal: Can J Anaesth
DOI: 10.1007/s12630-020-01700-w
sha: 05535a2d74a627341ddc0c4229435e5f55298c0e
doc_id: 1032898
cord_uid: vnshs7xx

nan

Approximately 5% of coronavirus disease (COVID-19) patients will require admission to an intensive care unit (ICU). 1 Among these patients, the most severe cases may be mediated by a late-onset systemic inflammatory response with cytokine dysregulation referred to as cytokine release syndrome (CRS). 2 Clinically, this results in fever, acute respiratory distress syndrome, multiorgan failure, and/or hemodynamic collapse due to distributive shock. Late-onset severe COVID-19 patients may respond to anti-inflammatory therapy without worsening the initial early viral infection. 3 We describe a case series of 15 COVID-19 patients admitted to ICU who received corticosteroids in the context of CRS. Cytokine release syndrome was identified as worsening hypoxemia or vasoplegia with rising C-reactive protein (CRP) or interleukin-6 levels without alternative clinical explanation. The Research Ethics Board at our local site approved this retrospective case series.

The characteristics of these patients are provided in the ). An average increase in the arterial partial pressure of oxygen/fraction of inspired oxygen (i.e., P/F) ratio of 44 was detected 24 hr after steroid administration (eFig. 2, available as ESM). Currently, four patients were discharged home, four patients remained in ICU, four patients were transferred to the medical ward, and three patients are deceased.

We present a subset of COVID-19 patients who presented with progressive respiratory failure along with progressive inflammatory biomarkers consistent with severe CRS. We found a significant clinical and biochemical association between corticosteroids and improved surrogate outcomes in late-onset CRS associated with COVID-19. Corticosteroids are indicated to treat CRS occurring from immune or chimeric antigen receptor therapy, but its use in weathering the cytokine storm in viral infection remains controversial, particularly if given early. 4 Other coronaviruses have an inverted ''V'' distribution of viral shedding, peaking ten days after the onset of symptoms and then decreasing rapidly. Consequently, the clinical deterioration occurring after ten days may be caused by dysregulated inflammation and not the virus itself, offering a window of opportunity for therapeutic intervention. 4 Our report is limited by several important factors. There was no control group and therefore no randomization of intervention, we examined surrogate outcomes of uncertain clinical relevance, and there was likely selection bias in determining who received steroids and what dose they received. We report very few patients from a single centre, making it difficult to generalize our results to other hospitals even after consideration of the biases present. Additionally, exact criteria for CRS are not available and the prognostic importance of CRS in COVID-19 patients remains to be determined.

The fear of giving corticosteroids is related to a possible risk of decreased viral clearance with unclear clinical significance. 5 Our report suggests the possibility of shortterm clinical improvements with corticosteroids and it highlights the need for urgent high-quality studies to determine whether steroid administration may meaningfully affect the outcomes of critically ill COVID-19 patients.

Funding statement None. Severe ARDS defined as PaO2/F I O2 ratio \ 100, Moderate ARDS defined as PaO 2 /F I O 2 ratio C 100 and \ 200. ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease; CRP = C-reactive protein; ICU = intensive care unit; N/A = not available; NP = nasal prongs; PaO 2 /F I O 2 = arterial partial pressure of oxygen/fraction of inspired oxygen.

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality

Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients

Pro/con clinical debate: steroids are a key component in the treatment of SARS. Pro: yes, steroids are a key component of the treatment regimen for SARS

Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations